A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Exclusion Criteria

• •Histology mixtured or Extensive-stage SCLC (per the Veterans Administration Lung Study Group (VALG) staging system).
• •Uncontrolled pleural effusion or pericardial effusion requiring recurrent drainage procedures
• •Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol, including significant liver disease
• •Malignancies other than SCLC within 5 years prior to study treatment initiation, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
• •Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within 5 months after the final dose of atezolizumab and 90 days after the final dose of tiragolumab, and 6 months for chemotherapy after the final dose of the chemotherapy treatment.
• •Active or history of autoimmune disease or immune deficiency
• •Uncontrolled or symptomatic hypercalcemia
• •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan.
• •Positive test result for HIV
• •Patients with active hepatitis B or hepatitis C virus
• •Active tuberculosis
• •Severe infections within 4 weeks prior to study treatment initiation, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
• •Significant cardiovascular disease
• •Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-CTLA4, anti-tigit, anti-PD-1, and anti-PD-L1 therapeutic antibodies
• •Unresolved toxic effects of grade 2 or higher (CTCAE 5.0), including grade ≥ 2 pneumonitis from previous therapy
• •Active EBV infection or known or suspected chronic active EBV infection at screening.